Global talent solution company The IN Group has boosted its capabilities in the life sciences recruitment industry with the acquisition of BioTalent.
BioTalent, a global leader in life sciences recruitment, has offices in the UK, US, and Europe. The company has specialist teams covering areas including biotechnology, digital health, and pharmaceutical, with a focus on research and development, regulatory, quality, medical, clinical as well as data science and AI.
The deal will combine The IN Group and BioTalent’s industry leading recruitment practices, creating a life sciences specialist division of over 50 experts.
The BioTalent UK team will move to The IN Group’s offices in Liverpool Street, London, to enable both teams to collaborate on growth plans. The investment strengthens The IN Group’s presence within the Life Sciences sector, while providing a growth platform for BioTalent within the industry, drawing on The IN Group’s existing portfolio of talent solutions.
James Cox, CEO & Co-Founder of BioTalent said: “Joining forces with The IN Group and Investigo’s existing life sciences team creates an exciting opportunity for our people at BioTalent as we look to realise our ambitious growth plans. Both companies have shared values and a commitment to creating a unique high performance culture. Combining BioTalent’s European expertise with Investigo’s exceptional life sciences offering in the US elevates our product offering for clients and candidates alike. Our team is excited about the future and about what we will achieve in this new combined offering as we take our business to the next level.”
“James and his team have built an incredible business that is leading the way in the life sciences staffing sector,” said Nick Baxter, CEO, The IN Group. “Coupled with our existing offering, our combined teams have an industry leading proposition that will excite customers and candidates alike. These are exciting times for The IN Group and we’re thrilled to be working with such a talented team as we continue our expansion.”
